SUZHOU, China – CD (Suzhou) Biopharma today announced that Alan Xu, PhD, Chief Executive Officer, will attend Bio International 2025, marking the company’s first participation in this premier global biotechnology conference. Dr. Xu will represent CD Biopharma as the company seeks to expand its network of industry partnerships and advance strategic business development initiatives.
“We’re thrilled to participate in Bio International 2025 as we enter an exciting phase of growth for CD Biopharma,” said Dr. Xu. “This represents an invaluable opportunity to connect with potential investors, strategic partners, and industry leaders while showcasing our innovative approach to cancer immunotherapy.”
CD Biopharma is focused on developing breakthrough oncology therapies, with its flagship asset CD-001 representing a significant milestone in the company’s pipeline. CD-001 is built on the company’s proprietary Bispecific Fusion Protein (BsFP) platform that targets PD-1 positive CD8+ T cells using an anti-PD-1 antibody and engineered IL-21 mutant. Following recent FDA clearance for its IND application, CD-001 has entered Phase I clinical trials, positioning the company at a critical inflection point.
During Bio International 2025, Dr. Xu will focus on exploring investment partnerships, identifying business opportunities, and advancing collaborations that will accelerate CD Biopharma’s innovative cancer immunotherapy programs and advance breakthrough treatments for patients with unmet medical needs.
About CD-001
CD-001, the company's leading clinical candidate, is built on its proprietary Bispecific Fusion Protein (BsFP) platform. This potential therapy, designed to target PD-1 positive CD8⁺ T cells using an anti-PD-1 antibody and engineered IL-21 mutant, aims to address unmet medical needs in oncology and viral infections.
Preclinical studies have demonstrated potent anti-tumor activity across multiple tumor models in mice, with a favorable safety and pharmacokinetic profile observed in non-human primate toxicology studies. The program has received IND clearance from both the U.S. Food and Drug Administration (FDA) and China National Medical Products Administration (NMPA) for advanced solid tumors, with first-in-human (FIH) solid tumor trials currently underway. The IND application for hematological malignancies has also received implicit approval from NMPA.
About CD (Suzhou) Biopharma
Founded in 2021, CD Biopharma is a rapidly advancing clinical-stage biotech company focused on developing innovative therapies across a broad spectrum of immunotherapy areas, including oncology, viral infections, and autoimmune diseases. The company's proprietary Bispecific Fusion Protein (BsFP) platform and IMmune-Enhanced (IME) cell technology, which enable advanced cell modification, continue to drive breakthrough research and clinical outcomes that transform patient care. CD Biopharma is headquartered in Suzhou, China, with additional research operations in Beijing, China.
